“Hot cross bun” is a potential imaging marker for the severity of cerebellar ataxia in MSA-C

Shuzhen Zhu1,2,7, Bin Deng2,7, Zifeng Huang2,7, Zihan Chang2,7, Hualin Li7, Hui Liu7, Yanjun Huang2, Ying Pan3, Yanping Wang9, Yin-Xia Zhao9, Ling-Ling Chan4, Yih-Ru Wu5, Eng-King Tan6,8 and Qing Wang2,6,8

To evaluate the correlation between “hot cross bun” sign (HCBs) and disease severity in multiple system atrophy (MSA). We recruited patients with probable and possible MSA with parkinsonism (MSA-P) or the cerebellar ataxia (MSA-C) subtypes. Clinical and imaging characteristics were collected and comparison was performed between MSA-C and MSA-P cases. Spearman test was used to evaluate the correlation between HCBs and other variables. Curve estimate and general linear regression was performed to evaluate the relationship between HCBs and the Scale for Assessment and Rating of Ataxia (SARA). Unified Multiple System Atrophy Rating Scale (UMSARS) IV was used to assess the severity of disease. Multinomial ordered logistic regression was used to confirm the increased likelihood of disability for the disease. Eighty-one MSA with HCBs comprising of 50 MSA-C and 31 MSA-P were recruited. We demonstrated that the severity of HCBs showed a positive linear correlation with SARA scores in MSA-C. Multinomial ordered logistic regression test revealed that the increase in the HCBs grade may be associated with an increased likelihood of disability for the disease severity in MSA, especially in those with cerebellar ataxia subtype. We demonstrated that HCBs is a potential imaging marker for the severity of cerebellar ataxia. The increase in the HCBs grade may be associated with an increased likelihood of disability in MSA-C, but not MSA-P cases, suggesting that it may be a useful imaging indicator for disease progression in Chinese patients with MSA-C.

https://doi.org/10.1038/s41531-021-00159-w

INTRODUCTION

Multiple system atrophy (MSA), is an adult-onset progressive age-related neurodegenerative disease, characterized by the presence of a 14 kDa protein α-synuclein inclusion. The clinical characteristics and neuro-pathogenesis of MSA are similar to those in Parkinson’s Disease (PD)1-3. There are two clinical forms including the parkinsonism subtype (MSA-P) with predominant parkinsonism, and cerebellar subtype (MSA-C) with predominant cerebellar ataxia in early stages. The pathology in MSA is mainly found in striato-nigral, olivopontocerebellar, and spinal cord structures and its pathological hallmark is glial cytoplasmic inclusions4-5. Conventional magnetic resonance imaging is frequently used in the diagnosis of MSA, and “hot cross bun” sign (HCBs) is widely accepted to be a valuable sign for the diagnosis of MSA6-14. HCB signal appears to be more pronounced as the disease progresses, suggesting that it may be a useful imaging indicator for disease progression. However, there is limited information on the exact relationship between HCBs signal and clinical phenotypes in MSA. Carré et al.15 in a recent study did not find a correlation between magnetic resonance imaging (MRI) features and the Scale for Assessment and Rating of Ataxia (SARA) in MSA patients. However, the study subjects were Caucasians and the predominant subtype is MSA-P in the study, and there were only 11 MSA-C patients.

To address the gap in current literatures, we investigated HCBs-positive MSA patients among mainland ethnic Han Chinese and profiled the clinical phenotypes in HCBs-positive MSA patients, assessed the relationship between HCBs and the severity of ataxia and independent viability. In addition, we explored whether there was heterogeneity in neuroimaging and clinical correlation between two subtypes (MSA-P vs MSA-C).

RESULTS

Demographic characteristics and clinical phenotypes in HCBs-positive MSA patients

Eighty-one patients including 50 (62%) MSA-C and 31 (38%) MSA-P were included (Table 1). Among MSA-C patients, 32 cases (64%) were probable MSA and 18 cases (36%) were possible MSA. Among MSA-P patients, 16 cases (51.7%) were probable MSA and 15 cases (48.3%) were possible MSA. Gender distribution and duration of diseases were not significantly different between patients with MSA-P and those with MSA-C (Table 1). Age at symptom onset and enrollment showed a significant difference between patients with MSA-P and those with MSA-C (Table 1). As expected, parkinsonian manifestation was more prevalent in cases with MSA-P and cerebellar symptoms were more prevalent in those with MSA-C, and autonomic failure was present in all cases (Table 2). The ratio of dementia in our MSA cases is ~15% (Table 2), which is similar to the report by O’Sullivan et al. 200816. The severity of cerebellar ataxia and disability differed significantly between patients with MSA-P and MSA-C (Table 2). The score of SARA and UMSARS-IV was higher in participants of MSA-C than those in MSA-P (Table 2). The Fleiss’ kappa and Cohen’s Kappa for inter and intra-rater reliability is 0.750 and 0.815. The Inter and intra-rater reliability for the grade of HCBs was showed in
HCBs positively correlated with the severity of ataxia in MSA-C patients

Spearman’s correlation coefficient for ranked data analysis was performed in the MSA, MSA-C, and MSA-P cases. The correlation analysis between the HCBs grade and disease duration was non-significant in MSA patients (rho = 0.179, p = 0.093). However, the HCBs was significantly correlated with cerebellar ataxia severity (SARA) (rho = 0.594, p < 0.001) global disability (UMSARS-IV) (rho = 0.560, p < 0.001). It is worth noting that a stronger correlation was found between the HCBs and SARA (rho = 0.784, p < 0.001) as well as UMSARS-IV (rho = 0.794, p < 0.001) in MSA-C patients than in MSA patients. However, the HCBs was not significantly associated with the SARA or UMSARS-IV in MSA-P patients. The detailed data are shown in Table 3.

The correlation analysis between the HCBs grade and atrophy of pons, middle cerebellar peduncles (MCP) were also assessed in our study. The HCBs grade was significantly correlated with atrophy of pons (rho = -0.311, p = 0.0005) and MCP (rho = -0.411, p < 0.001) in MSA patients. The significant correlations between HCBs and MCP was also found in MSA-C and MSA-P patients (Table 3). A General Linear Model with univariate analysis showed that there was a significant positive linear correlation between the HCBs grade and SARA scores (adjusted R² = 0.573, P < 0.001) in MSA-C cases after adjusted for atrophy of pons, atrophy of MCP and disease duration (Table 4, Fig. 1 and Fig. 2).

An increase in the HCBs grade is associated with an increased likelihood of disability in MSA-C patients

Recent studies suggested that many factors, such as age of onset,16–18 gender,17,18 disease duration,17 and atrophy of pons,7,17 might involve in the progression of MSA; however, owing to the differences of population and main end-point indicators in studies, the conclusions of these studies were inconsistent. In our study, age of onset, gender, disease duration, and atrophy of pons were included for analysis.

To investigate these factors, multinomial ordered logistic regression test was performed. Possible risk factors, such as age at symptom onset, sex, disease duration, HCBs, atrophy of pons, atrophy of MCP were included into the analysis. We showed that the increase in the HCBs grade may be associated with an increased likelihood of disability in MSA-C patients after adjusting for sex, age at symptom onset, atrophy of pons, atrophy of MCP and disease duration (Table 5). With the increase of HCBs grade, the risk of severe disability gradually increased (Table 5). The risk of disability in MSA-C patients with HCBs grade 5 was 35.71, 83.33, and 500 times higher than that those with grade 4, 3, and 2 (Table 5). Age of onset, disease duration, and atrophy of pons

Table 1. Demographic characteristics of MSA patients.

|                        | Overall | MSA-C | MSA-P | p value |
|------------------------|---------|-------|-------|---------|
| (n = 81)               | (n = 50) | (n = 31) |       |         |
| Sex                    |         |       |       |         |
| Woman                  | 30 (38%)| 22 (44%)| 10 (32%)| 0.293†  |
| Men                    | 51 (62%)| 28 (56%)| 21 (68%)|         |
| Age                    |         |       |       |         |
| Enrollment             | 57.5 (7.1) | 56.0 (6.6) | 59.8 (7.4) | 0.018** |
| Symptoms onset         | 55.7 (7.2) | 53.5 (6.4) | 58.5 (7.5) | 0.005** |
| Duration of disease    | 2.0 (1.0–3.0) | 2.0 (1.0–2.3) | 2.0 (1.0–4.0) | 0.370†  |

Comparison was conducted between MSA-C and MSA-P groups. Data are n (%), mean SD, or median (IQR), unless stated otherwise. *Significant difference between MSA-C and MSA-P patients, P < 0.05. **Significant difference between MSA-C and MSA-P patients, P < 0.01. †Based on χ² test, ‡Based on t test, §Based on Mann–Whitney test with significance level of 0.05 (two-tailed).

Table 2. Clinical and imaging characteristics were compared between MSA-C and MSA-P patients with HCBs.

|                        | Overall | MSA-C | MSA-P | p value |
|------------------------|---------|-------|-------|---------|
| (n = 81)               | (n = 50) | (n = 31) |       |         |
| Autonomic failure      |         |       |       |         |
| Orthostatic hypotension| 44 (54%)| 30 (60%)| 14 (45%)| 0.193†  |
| Urinary incontinence   | 8 (10%) | 4 (8%) | 4 (13%)| 0.474†  |
| Incomplete bladder empty| 49 (60%)| 28 (56%)| 21 (68%)| 0.293†  |
| Constipation           | 53 (65%)| 33 (66%)| 20 (65%)| 0.891†  |
| Any                    | 81 (100%)| 50 (100%)| 31(100%)| …        |
| Cerebellar dysfunction |         |       |       |         |
| Gait ataxia            | 68 (84%)| 47 (94%)| 21 (68%)| 0.004‡  |
| Limb ataxia            | 68 (84%)| 46 (92%)| 22 (71%)| 0.026‡  |
| Cerebellar dystarhnia  | 28 (35%)| 23 (46%)| 5 (16%)| 0.008‡  |
| Nystagmus              | 8 (10%) | 8 (16%)| 0 (0%) | 0.021‡  |
| Any                    | 74 (91%)| 50 (100%)| 24 (77%)| 0.001‡  |
| Parkinsonism           |         |       |       |         |
| Bradykinesia           | 43 (53%)| 14 (28%)| 29 (94%)| 0.001‡  |
| Rigidity               | 39 (48%)| 12 (24%)| 27 (8%) | 0.001‡  |
| Postural instability   | 46 (57%)| 25 (50%)| 21 (68%)| 0.117†  |
| Resting tremor         | 37 (46%)| 10 (20%)| 27 (87%)| 0.001‡  |
| Any                    | 48 (59%)| 17 (34%)| 31 (100%)| 0.001‡  |
| Corticospinal dysfunction |     |       |       |         |
| Babinski sign          | 43 (53%)| 25 (50%)| 18 (58%)| 0.480‡  |
| Atypical symptoms      | 12 (15%)| 8 (16%)| 4 (12%) | 0.760‡  |
| Dementia               |         |       |       |         |
| Neurological scores    |         |       |       |         |
| SARA                   | 11.0 (4.0–16.5) | 5.8–21)| 5.0 (2.0–13.0) | 0.001‡  |
| UMSARS-IV              | 2.0 (2.0–4.0) | 3.5 (2.0–4.0)| 3.0 (2.0–5.0)| 0.775‡  |
| Imaging features       |         |       |       |         |
| HCB vertical line      | 1.57 (1.44–1.58) | 1.45–1.56 | 1.35–1.71 | 0.434‡  |
| HCB horizon line       | 1.49 (0–1.89) | 1.73–0.95 | 0.170–0.70 | 0.169‡  |
| Atrophy of pons        | 1.66 (1.48–1.89)| 1.67 (1.48–1.87)| 1.66 (1.48–1.89)| 0.694‡  |
| Atrophy of MCP         | 1.05 (0.89–1.24)| 1.04 (0.92–1.23)| 1.08 (0.85–1.34)| 0.953‡  |
| HCB grade              | 3 (2–4) | 3 (2–4) | 3 (2–4) | 0.465‡  |

Data are n (%), or median (IQR), unless stated otherwise. *Based on χ² test, significance level of 0.05 (two-tailed). †Based on Fisher’s exact test if any cell has fewer than ten observations with level of significance set to 0.05 (two-tailed). ‡Based on Mann–Whitney test with significance level of 0.05.

Significant difference between MSA-C and MSA-P patients, P < 0.05. UMSARS Unified Multiple System Atrophy Rating Scale, MSA-C multiple system atrophy (cerebellar subtype), MSA-P multiple system atrophy (parkinsonism subtype). MCP middle cerebellar peduncles. SARA Scale for Assessment and Rating of Ataxia.
were not associated with an increased likelihood of disability in MSA patients in our study (Table 5).

DISCUSSION

There is limited literature on the correlation of HCBs with clinical manifestations and disease severity. Our study identified several novel observations. We showed that in MSA-C, the HCBs grade was positively correlated with the severity of cerebellar ataxia as assessed by SARA. The increase in the HCBs grade may be correlated with the MSA-C subtype progression and severity but not for the MSA-P subtype. MSA-C subtype appears more prevalent in Asians than in Caucasians.

Some investigators suggested that the microstructural changes within the transverse and longitudinal fibers predated the formation of the HCBs and may be correlated with the MSA clinical presentations. Here we analyzed the correlation between the HCBs grade and the severity of cerebellar ataxia. Spearman’s correlation showed that the HCBs grade was significantly correlated with each SARA item in MSA-C patients, including gait, stance, sitting, speech disturbance, finger chase, and nose–finger tests (Table 4 and Fig. 2). Linear regression analysis showed that the HCBs grade and SARA scores had a positive linear relationship. These findings demonstrated that the high signal on T2-weighted images of HCBs could be a potential indicator of the severity of cerebellar ataxia in MSA-C subtype.

A “HCB” sign in the pontine basis (PB) was seen in 63.3% MSA patients. These pontine abnormalities became more prominent as MSA-C features advanced. Watanabe, et al. found that the atrophy of PB showed a significant correlation particularly with the interval following the appearance of cerebellar symptoms in MSA-C (r = 0.76 and P < 0.01), but the relationship between atrophy and functional status was highly variable among the individuals. In this study, we further evaluated the relationship between the atrophy of pons and middle cerebellar peduncles with functional status (disability) and no relationship was found. Owing to the fact that the occurrence of HCBs was earlier than the obvious atrophy of pons and could be graded according to the disease severity, indicating HCBs may be a more sensitive imaging indicator. In our study, among the case with grade 1–3, 28.6% was severe disability; however, among the case with grade 4–5, the proportion jumped to 78.1%. ROC curve analysis showed the AUC is 0.76 (0.65–0.86). One recent study in Caucasians reported no correlation between MRI features and SARA in MSA-C. Methodological

---

**Table 3.** Correlation analysis of HCBs grade with variables in MSA patients.

| Variables               | Overall (n = 81) | MSA-C (n = 50) | MSA-P (n = 31) |
|-------------------------|------------------|----------------|----------------|
|                         | r                | p<sup>†</sup>  | r              | p<sup>†</sup>  | r              | p<sup>†</sup>  |
| Autonomic failure       |                  |                |                |                |                |                |
| Orthostatic hypotension | −0.085           | 0.453          | −0.061         | 0.675          | −0.179         | 0.335          |
| Urinary incontinence    | 0.119            | 0.288          | 0.139          | 0.337          | 0.089          | 0.636          |
| Incomplete bladder empty| 0.043            | 0.706          | −0.026         | 0.859          | 0.195          | 0.294          |
| Constipation            | 0.180            | 0.108          | 0.177          | 0.220          | 0.186          | 0.316          |
| Cerebellar dysfunction  |                  |                |                |                |                |                |
| Gait ataxia             | 0.177            | 0.114          | 0.021          | 0.885          | 0.314          | 0.086          |
| Limb ataxia             | 0.308            | 0.005          | 0.183          | 0.203          | 0.442          | 0.013          |
| Cerebellar dysarthria    | 0.261            | 0.019          | 0.319          | 0.024          | 0.091          | 0.627          |
| Nystagmus               | −0.135           | 0.230          | −0.194         | 0.178          | ...            | ...            |
| Parkinsonism            |                  |                |                |                |                |                |
| Bradykinesia            | −0.041           | 0.719          | 0.084          | 0.563          | −0.219         | 0.236          |
| R rigidity              | −0.116           | 0.304          | −0.043         | 0.766          | −0.183         | 0.325          |
| Postural instability    | −0.161           | 0.152          | −0.163         | 0.258          | −0.123         | 0.509          |
| Resting tremor          | −0.059           | 0.604          | 0.110          | 0.447          | −0.277         | 0.132          |
| Corticospinal dysfunction|                |                |                |                |                |                |
| Babinski sign           | 0.174            | 0.120          | 0.196          | 0.173          | 0.166          | 0.373          |
| Atypical symptoms       | −0.081           | 0.471          | −0.110         | 0.446          | −0.022         | 0.906          |
| Neurological Scores     |                  |                |                |                |                |                |
| SARA                    | 0.594            | <0.001         | 0.788          | <0.001         | 0.326          | 0.073          |
| UMSARS-IV               | 0.560            | <0.001         | 0.794          | <0.001         | 0.154          | 0.408          |
| Imaging features        |                  |                |                |                |                |                |
| Atrophy of pons         | −0.311           | 0.005          | −0.271         | 0.057          | −0.357         | 0.048          |
| Atrophy of MCP          | −0.411           | <0.001         | −0.383         | 0.006          | −0.434         | 0.015          |
| Disease duration        | 0.179            | 0.093          | 0.109          | 0.520          | 0.376          | 0.037          |
| Age on symptom onset    | −0.061           | 0.587          | −0.582         | 0.573          | −0.132         | 0.479          |

<sup>†</sup>Based on Spearman test, significance level of 0.05 (two-tailed).

UMSARS, Unified Multiple System Atrophy Rating Scale; MSA-C, multiple system atrophy (cerebellar subtype); MSA-P, multiple system atrophy (parkinsonism subtype); MCP, middle cerebellar peduncles.
These variables were found, suggesting that HCBs may not be a good indicator for the severity in MSA-P subtype. In all other variables of significance between MSA-C and MSA-P in our cohort, we only observed the differences may explain the varying result of our study. The study included MSA-C cases with and without HCBs signatures; however, we only included MSA-C cases with confirmed HCBs signatures. Furthermore, there were only 11 patients with MSA-C subtype compared with 51 cases in our study.

Interestingly, we did not find any correlation between the HCBs and SARA scores in the MSA-P subtype, strongly suggesting differences in pathophysiology between C and P subtypes. Based on the clinical manifestations of MSA-C and MSA-P in previous reports and our study, these two subtypes have great clinical heterogeneity. Although the grade of HCBs was not different compared with 51 cases in our study. We recruited patients from the Chinese Parkinson disease alliance, Department of Neurology of Zhujiang hospital, Southern Medical University. Images of MSA patients with HCBs on T2-weighted MRI were prospectively collected over a 7-year period. MSA cases were diagnosed according to the clinical criteria described by Gilman et al. and Low et al. Criteria for the diagnosis of probable MSA is that a sporadic, progressive, adult (>30 y)–onset disease characterized by autonomic failure involving urinary incontinence (inability to control the release of urine from the bladder, with erectile dysfunction in males) or an orthostatic decrease of blood pressure within 3 min of standing by at least 30 mm Hg systolic or 15 mm Hg diastolic and poorly levodopa-responsive parkinsonism (bradykinesia with rigidity, tremor, or postural instability) or a cerebellar syndrome (gait ataxia with cerebellar dysarthria, limb ataxia, or cerebellar oculomotor dysfunction). Criteria for possible MSA is that a sporadic, progressive, adult (>30 y)–onset disease characterized by parkinsonism (bradykinesia with rigidity, tremor, or postural instability) or a cerebellar syndrome (gait ataxia with cerebellar dysarthria, limb ataxia, or cerebellar oculomotor dysfunction) and at least one feature, suggesting autonomic dysfunction (otherwise unexplained urinary urgency, frequency or incomplete bladder emptying, erectile dysfunction in males, or significant orthostatic blood pressure decline that does not meet the level required in

Table 4. Relationship between HCBs and severity of ataxia as assessed by score of sums and each item of SARA.

| Variables                | Overall (n = 81) |  |  |  | MSA-C (n = 50) |  |  |  | MSA-P (n = 31) |  |  |
|--------------------------|-----------------|---|---|---|-----------------|---|---|---|-----------------|---|---|
|                          | r²               | p<0.05 | Adjusted r² | p<0.05 | r²               | p<0.05 | Adjusted r² | p<0.05 | r²               | p<0.05 | Adjusted r² | p<0.05 |
| SARA                     | 0.451            | 0.339 | <0.001 | 0.634 | 0.573 | <0.001 | 0.392 | 0.206 | 0.148 |
| Gait                     | 0.510            | 0.432 | <0.001 | 0.705 | 0.619 | <0.001 | 0.444 | 0.166 | 0.808 |
| Stance                   | 0.511            | 0.449 | <0.001 | 0.759 | 0.705 | <0.001 | 0.485 | 0.298 | 0.335 |
| Sitting                  | 0.462            | 0.410 | <0.001 | 0.634 | 0.573 | <0.001 | 0.394 | 0.290 | 0.748 |
| Speech disturbance       | 0.304            | 0.205 | 0.221 | 0.363 | 0.220 | 0.081 | 0.389 | 0.167 | 0.887 |
| Finger–finger test        | 0.386            | 0.308 | 0.005 | 0.467 | 0.347 | 0.005 | 0.409 | 0.195 | 0.775 |
| Nose–finger test          | 0.454            | 0.393 | <0.001 | 0.603 | 0.526 | <0.001 | 0.373 | 0.145 | 0.953 |
| Fast alternating hand movements | 0.383 | 0.314 | 0.002 | 0.502 | 0.404 | 0.001 | 0.389 | 0.167 | 0.887 |
| Heel–shin slide           | 0.397            | 0.330 | 0.001 | 0.554 | 0.467 | <0.001 | 0.410 | 0.195 | 0.772 |

†Based on General Linear Model with univariate analysis, atrophy of pons, atrophy of MCP and disease duration were analyzed as covariates. significance level of 0.05 (two-tailed).

UMSARS Unified Multiple System Atrophy Rating Scale, MSA-C multiple system atrophy (cerebellar subtype), MSA-P multiple system atrophy (parkinsonism subtype).

Fig. 1 The Scatter plot showed the correlation between SARA sum score and HCBs grade. Each dot represented on case. The red solid dot represented case in MSA-C group and the green hollow dot represented case in MSA-P group. 95% confidence interval (CI) was shown in shadow area.
probable MSA) and at least one of the additional features as follows: (1) Babinski sign with hyperreflexia or stridor for possible MSA-P or MSA-C; (2) rapidly progressive parkinsonism or poor response to levodopa or postural instability within 3 y of motor onset or gait ataxia, cerebellar dysarthria, limb ataxia, cerebellar oculomotor dysfunction or dysphagia within 5 y of motor onset or atrophy on MRI of putamen, middle cerebellar peduncle, pons, cerebellum or hypometabolism on FDG-PET in putamen, brainstem, cerebellum for possible MSA-P; (3) Parkinsonism (bradykinesia and rigidity) or atrophy on MRI of putamen, middle cerebellar peduncle, or pons or hypometabolism on FDG-PET in putamen or presynaptic nigrostriatal dopaminergic denervation on SPECT or PET for possible MSA-C. Patients with both MSA-C and MSA-P were designated by onset of first symptom (cerebellar ataxia or parkinsonism). Briefly, inclusion criteria were: (i) MSA-P or MSA-C patients; (ii) HCBs on T2-weighted MRI; (iii) age of symptom onset was >30 years old.

Our exclusion criterion was (i) cerebellar ataxia or parkinsonism or autonomic failure might be owing to other central nervous system disease, such as stroke or paraneoplastic syndrome or hereditary cerebellar ataxia; (ii) family history of ataxia or parkinsonism; (iii) classic pill-rolling rest tremor; (iv) clinically significant neuropathy; (v) hallucinations not induced by drugs; (vi) onset after age 75 year; (vii) white matter lesions suggesting multiple sclerosis. In our study, dementia was observed as a possible feature for MSA patients and was not considered as a non-supporting feature for MSA patients. We conducted this according to (i) O’Sullivan, S. S. et al.18, and Iva Stankovic et al., Movement Disorders Society MSA (MODIMSA) Study Group24. At first, 86 cases were enrolled, but five cases were excluded (one case complicating with cerebellar peduncle infarction, two cases with family history, two cases showing positive paraneoplastic antibody). The study was approved by the ethics committees of the Zhjiang Hospital of Southern Medical University, China (2018-SJNK-002).

Table 5. Factors associated with disabilities in MSA patients.

| Risk factors        | OR   | Overall (n = 81) | OR 95% CI | OR (n = 50) | OR 95% CI | OR (n = 31) | OR 95% CI |
|---------------------|------|-----------------|-----------|-------------|-----------|-------------|-----------|
|                     | OR   | Overall (n = 81) | OR 95% CI | OR (n = 50) | OR 95% CI | OR (n = 31) | OR 95% CI |
| Age                 |      |                 |           |             |           |             |           |
| Symptom onset       | 1.020| 0.551           | 0.955–1.089| 0.937       | 0.206     | 0.846–1.037 | 1.095     | 0.141     | 0.970–1.237|
| Sex                 |      |                 |           |             |           |             |           |
| Woman               | 3.889| 0.008           | 1.428–10.591| 3.058       | 0.121     | 0.745–12.5  | 10.753    | 0.013     | 1.667–71.429|
| Man                 |      |                 |           |             |           |             |           |
| Disease duration    | 1.002| 0.986           | 0.802–1.252| 1.003       | 0.988     | 0.694–1.448 | 0.920     | 0.652     | 0.639–1.323|
| Atrophy             |      |                 |           |             |           |             |           |
| Pons                | 0.184| 0.229           | 0.012–2.898| 0.068       | 0.267     | 0.001–7.826 | 0.445     | 0.691     | 0.008–24.074|
| MCP                 | 7.232| 0.159           | 0.460–113.683| 2.865      | 0.658     | 0.027–304.440| 7.284     | 0.337     | 0.127–418.949|
| HCB grade           |      |                 |           |             |           |             |           |
| 1                   | 0.005| <0.001          | 0.001–0.041| 0.000       | <0.001    | 0.000–0.005 | 0.016     | 0.031     | 0.068   |
| 2                   | 0.016| <0.001          | 0.002–0.100| 0.002       | <0.001    | 0.000–0.026 | 0.121     | 0.232     | 0.004–3.864|
| 3                   | 0.019| <0.001          | 0.003–0.116| 0.012       | 0.001     | 0.001–0.164 | 0.010     | 0.008     | 0.029   |
| 4                   | 0.068| 0.002           | 0.013–0.371| 0.028       | 0.004     | 0.003–0.311 | 0.088     | 0.132     | 0.004–2.080|
| 5                   | 1     | 1               | 1          | 1           |           |             |           |

1Based on Multinomial Ordinal logistic regression test, significance level of 0.05 (two-tailed). MSA-C multiple system atrophy (cerebellar subtype), MSA-P multiple system atrophy (parkinsonism subtype), MCP middle cerebellar peduncles, OR odds ratio.
Formal consent for publication were obtained from all participants. All participants have provided written informed consent to take part in the study.

Clinical assessment

Clinical data including demographics (sex, age on enrollment and symptom onset, disease duration), and presence of dysautonomia (orthostatic hypotension (a reduction of systolic blood pressure by at least 30 mm Hg, or a reduction of diastolic blood pressure by at least 15 mm Hg after 3 min of standing from a previous 3-minute interval in the recumbent position), urinary incontinence, incomplete bladder empty (measurement of urine residual volume (RV) by ultrasound revealing incomplete bladder emptying of 100 ml as described by Gilman et al. and Low et al.), constipation, cerebellar dysfunction (gait ataxia, limb ataxia, cerebellar dysarthria, nystagmus), Parkinsonism (Bradykinesia, rigidity, postural instability, resting tremor), corticospinal dysfunction (Babinski sign), dementia (defined as impairment of at least two cognitive domains and leading to substantial and apparently permanent impairment of ability to perform tasks of daily living. (DSM-IV, 1994)18,25, neurological scores (SARA score, Unified Multiple System Atrophy Rating Scale (UMSARS-IV)). The severity of cerebellar ataxia was assessed using the SARA as described by Subramony26. Eight items are included in this scale, including gait, stance, sitting, speech disturbance, finger chase, nose–finger test, fast alternating hand movements, and heel–shin slide. The maximum score is 40, indicating the most serious ataxia. Global disability was assessed with the fourth part of the Unified Multiple System Atrophy Rating Scale IV (UMSARS-IV) in MSA patients as described by Wenning GK27. UMSARS-IV is a disability scale, which was graded as follows according to the severity of disability: 1. life is completely independent, and patients can finish all housework; 2. life is not completely independent, and some housework cannot be finished independently; 3. life is somewhat dependent, and more than half of housework cannot be finished independently; 4. life is very dependent on others, and only a small amount of housework can be finished independently; 5. self-care is impossible, and the patient is bedridden. Grade 1–3 was defined to mild disability, and Grade 4–5 defined as severe disability.
assessed by the two Neurologists, the final size for analysis was decided by consensus between the two Neurologists. Representative brain MRI of MSA cases was shown in Figs 3–5.

**Statistical methods**

We compared clinical variables between MSA-C and MSC-P group with the Mann–Whitney test or Student’s t test or χ² tests when each cell had ten or more observations. We used Fisher’s exact test to compare symptoms between groups when cells had fewer than ten observations. We evaluated the correlation of HCBs with other clinical and imaging variables with spearman’s correlation analysis. Curve estimate and general linear model with univariate analysis were used to analyze the relationships between the HCBs grades and SARA scores; atrophy of pons, atrophy of MCP and disease duration were analyzed as covariates. We used multinominal ordered logistic regression to evaluate the independent risk factors for disability of MSA patients. Statistical analysis was performed with SPSS 23.0 for Windows (SPSS, Chicago, IL). The inter- and intra-rater reliability was assessed using Fleiss’ kappa and Cohen’s Kappa implementation in the R package irr.30,31

**DATA AVAILABILITY STATEMENT**

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Received: 27 July 2020; Accepted: 8 January 2021; Published online: 15 February 2021

**REFERENCES**

1. Zhang, Y. et al. Multiple comorbid sleep disorders adversely affect quality of life in Parkinson’s disease patients. *NPJ Parkinson’s Dis.* 6, 25 (2020).
2. Fanning, S., Selkoe, D. & Dettmer, U. Parkinson’s disease: proteinopathy or lipi-dopathy? *NPJ Parkinson’s disease* 6, 3, https://doi.org/10.1038/s41531-019-0103-7 (2020).
3. Xu, J. et al. Mitochondrial creatine kinase is decreased in the serum of idiopathic Parkinson’s disease patients. *Aging Dis.* 10, 601–610 (2019).
4. Xie, T. et al. Comparison of clinical features in pathologically confirmed PSP and MSA patients followed at a tertiary center. *NPJ Parkinson’s Dis.* 1, 15007 (2015).
5. Carli, G. et al. In-vivo signatures of neurodegeneration in isolated rapid eye movement sleep behaviour disorder. *Eur. J. Neurol.* 27, 1285–1295 (2020).
6. Seki, M. et al. Diagnostic potential of multimodal MRI markers in atypical Parkinsonian disorders. *J. Parkinsonism.* 9, 681–691 (2019).
7. Mangesius, S. et al. Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers. *Parkinsonism Relat. Disord.* 77, 57–63 (2020).
8. Massey, L. A. et al. Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. *Mov. Disord.* 27, 1754–1762 (2012).
9. Ozaki, K. et al. Prevalence and clinicoradiological features of spinocerebellar ataxia type 34 in a Japanese ataxia cohort. *Parkinsonism Relat. Disord.* 65, 238–242 (2019).
10. Goldman, J. S. et al. Multiple system atrophy and amyotrophic lateral sclerosis in a family with hexanucleotide repeat expansions in C9orf72. *JAMA Neurol.* 71, 771–774 (2014).
11. Hardiman, O. et al. Measuring network disruption in neurodegenerative diseases: new approaches using signal analysis. *J. Neurol. Neurosurg. Psychiatry* 90, 1011–1020 (2019).
12. Kriemer, F. et al. Abnormalities on structural MRI associate with faster disease progression in multiple system atrophy. *Parkinsonism Relat. Disord.* 58, 23–27 (2019).
13. Sugiyama, A. et al. Vertical pons hypertensity and hot cross bun sign in cerebellar-type multiple system atrophy and spinocerebellar ataxia type 3. *BMC Neurol.* 20, 157 (2020).
14. Kim, M. et al. Differential value of brain magnetic resonance imaging in multiple system atrophy cerebellar phenotype and spinocerebellar ataxias. *Sci. Rep.* 9, 17329 (2019).
15. Carre, G. et al. Brain MRI of multiple system atrophy of cerebellar type: a prospective study with implications for diagnosis criteria. *J. Neurol.* 267, 1269–1277 (2020).
16. Ben-Shlomo, Y., Wenning, G. K., Tison, F. & Quinn, N. P. Survival of patients with pathologically proven multiple system atrophy: a meta-analysis. *Neurology* 48, 384–393 (1997).

---

**Image analysis**

Brain MRI examination was performed using a 3-T MR scanner (Achieva, Siemens Healthineers, Germany) with a 16-channel head coil. Three-dimensional T1-weighted images were acquired with axial orientation using a 3.0T Discovery. Scan parameters were as follows: field of view (FOV): 230 × 184 × 96 mm; voxel: 1.64 × 1.64 × mm; Matrix: 140 × 112 × 48 slices; repetition time 3.7 ms, echo time of 1.69 ms, and slice thickness of 2 mm. The sequence type and acquisition parameters for the T2-weighted images were as follows: T2-weighted spin echo sequence: coil selection: SENSE-NV-16; FOV: AP 215 mm, RL 197 mm, FH 125 mm; Voxel size AP 0.575 mm, RL 0.72 mm, Slice thickness 7 mm, Stacks fold-over direction RL, TR 3000 ms, TE 80 ms. The grade of the HCBs was assessed according to criteria reported by Horimoto et al.32 The HCBs was graded as follows: no change appeared = 0; a vertical T2 high-signal line began to appear = 1; only a clear vertical line appeared = 2; a horizontal line began to appear following a vertical line appearance = 3; both a clear horizontal and a vertical line appeared (cross line completed) = 4; and the ventral pons in front of the horizontal line showed T2 high signal or the ventral pons decreased in size with pontine base atrophy = 5. Grade 1–3 was defined as unclear HCBs and 4–5 was defined to clear completed HCBs. The HCBs was graded by three independent neuroradiologists. For the intra-rater reliability study, before the evaluations, evaluators underwent the same 24-h training to standardize the evaluation procedure. After the training, a total of 30 participants were randomly selected. Every neuroradiologist evaluated HCBs twice and the intra-rater reliability was assessed. For the inter-reliability study, all participants were included. The three evaluators did not have access to the values of each other’s evaluations. If the rating results are inconsistent, the final score can only be obtained after the agreement of at least two neuroradiologists. The representative images of different grade of HCBs were shown in Fig. 3a–e.

In addition, the length of the horizontal line and vertical line of HCBs, the atrophy of pons and the atrophy of MCP were also evaluated as shown in Figs 4 and 5. Methods for measuring MCP widths was referred to Sako et al.28 Measurements were performed using MRicron (http://www.mccauslandcenter.sc.edu/mricro/mricron/). The slice with maximal size was adopted. Widths of both sides were averaged for the MCP. The method used for size measurements of the middle cerebellar peduncle was shown in Fig. 4. The anteroposterior diameter of pons was measured according to the method described by Massey, et al., 201333, Briefly, elliptical regions were placed over the pons and the midbrain in the midsagittal slice. Two lines were drawn to define the major axes of the ellipses, corresponding to oblique superior-inferior axes (blue line, Fig. 5). The maximal measurement perpendicular to the major axis was taken, representing the anteroposterior diameter of the pons (Orange line, Fig. 5). The posterior border of the pons was clearly identifiable and did not include the pontine tegumentum. The methods used for size measurements of the anteroposterior diameter of pons are shown in Fig. 5. Two independent movement disorder specialist (YP Pan) were blinded to the clinical information, evaluated the size three times, and the average value was taken. In cases of discrepancy between sizes

---

**Fig. 5 Schematic diagram of the measurement of the anteroposterior diameter of the pons. a** T1-weighted image on conventional midsagittal MRI. **b** Regions of interest were placed over the pons and the midbrain in the midsagittal slice. Two vertical lines were drawn. Blue line defined the superior-inferior axes. Orange line represented the anteroposterior diameter.
17. Watanabe, H. et al. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. *Brain: J. Neurol.* **125**, 1070–1083 (2002).
18. O’Sullivan, S. S. et al. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. *Brain: J. Neurol.* **131**, 1362–1372 (2008).
19. Kollensperger, M. et al. Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. *Mov. Disord.* **25**, 2604–2612 (2010).
20. Horimoto, Y. et al. Longitudinal MRI study of multiple system atrophy - when do the findings appear, and what is the course? *J. Neurol.* **249**, 847–854 (2002).
21. Stankovic, I. et al. Cognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group. *Mov. Disord.* **29**, 857–867 (2014).
22. Gilman, S. et al. Second consensus statement on the diagnosis of multiple system atrophy. *Neurology* **71**, 670–676 (2008).
23. Low, P. A. et al. Natural history of multiple system atrophy in the USA: a prospective cohort study. *Lancet Neurol.* **14**, 710–719 (2015).
24. Stanzani-Maserati, M. et al. Cognitive and sleep features of multiple system atrophy: review and prospective study. *Eur. Neurol.* **72**, 349–359 (2014).
25. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association. (1994).
26. Subramony, S. H. SARA—a new clinical scale for the assessment and rating of ataxia. *Nat. Clin. Pract. Neurol.* **3**, 136–137 (2007).
27. Wenning, G. K. et al. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). *Mov. Disord.* **19**, 1391–1402 (2004).
28. Sako, W. et al. “One line”: a method for differential diagnosis of parkinsonian syndromes. *Acta Neurol. Scand.* **140**, 229–235 (2019).
29. Massey, L. A. et al. The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy. *Neurology* **80**, 1856–1861 (2013).
30. Fleiss, J. L. Measuring nominal scale agreement among many raters. *Psychol. Bull.* **76**, 378–382 (1971).
31. Cohen, J. A coefficient of agreement for nominal scales. *Educ. Psychol. Meas.* **20**, 37–46 (1960).

**ACKNOWLEDGEMENTS**

This work was supported by the National Key R&D Program of China (Grant no.: 2017YFC1310200), National Natural Science Foundation of China (no.: 81873777, 82071414), Guangdong Provincial Key Laboratory of Shock and Microcirculation, Initiated Foundation of Zhujiang Hospital (no.: 02020318005), Science and Technology Program of Guangdong of China (no.: 2020A0505100037) and Leading Talent in Talents Project Guangdong High-level Personnel of Special Support Program to QW; and National Science Foundations of Guangdong of China (no.: 2017A030313672, 2019A1515010281), China Postdoctoral Science Foundation (no.: 2019M652971), Postdoctoral support project of Shunde District, Foshan City, Guangdong Province (no.: 360209) to SZZ. We greatly thank Professor Zhibo Wen (Department of Radiology, Zhujiang Hospital) for his guidance on the imaging part.

**AUTHOR CONTRIBUTIONS**

Conceived and designed the study: Q.W. and S.Z.Z. Performed the study: S.Z.Z., B.D., and Z.F.H. Revised the paper for intellectual content: E.K.T., Y.X.C., H.L., Y.J.H., Z.H.C., L. L.C., and B.D. Data statistics and analysis: Y.P., Y.F.W., Y.R.W., S.Z.Z., LLC, Y.X.C., and B. D. Wrote the paper: S.Z.Z., D.B., E.K.T., and Q.W. All authors read and approved the final manuscript.

**COMPETING INTERESTS**

The authors declare no competing interests.

**ADDITIONAL INFORMATION**

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41531-021-00159-w.

Correspondence and requests for materials should be addressed to E.-K.T. or Q.W.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021